In today's Pharmaceutical Executive Daily, GSK enters an exclusive collaboration with Sino Biopharmaceutical's CTTQ ...

An exclusive China launch collaboration positions CTTQ to lead importation, distribution, hospital access, and promotion, while GSK retains marketing authorization and oversight of regulatory, quality ...

Tris Pharmaceutical’s founder and CEO Ketan Mehta spoke with Pharmaceutical Executive about the company’s history and how ...

Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...

Madrigal licensed ARO-PNPLA3 under an exclusive global agreement valued above $1 billion, including $25 million upfront, up to $975 million milestones, and tiered royalties. PNPLA3 I148M homozygosity ...

White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...

TRuE-AD4 enrolled adults with 10%–20% BSA moderate atopic dermatitis and prior inadequate response, intolerance, or ...

FDA’s three-month extension was triggered by a major amendment after the agency requested additional information during priority review, necessitating more time to evaluate newly submitted materials.

Deal terms include $2.0 billion upfront and up to $200 million milestone-based consideration, with closing anticipated in ...

In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...

FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...